Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus best available treatment vs best available treatment in steroid-refractory acute graft-versus-host disease
2014-004267-20Phase 2Terminated
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Overall response rate at day 28. Started Mar 2015; status: terminated.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2014-004267-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004267-20.